MERUS N V's ticker is MRUS and the CUSIP is N5749R100. A total of 94 filers reported holding MERUS N V in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,445,572 | +7.6% | 61,305 | +20.2% | 0.00% | – |
Q2 2023 | $1,343,119 | +41.2% | 51,011 | -1.3% | 0.00% | – |
Q1 2023 | $950,949 | +17.0% | 51,682 | -1.6% | 0.00% | – |
Q4 2022 | $812,500 | -19.5% | 52,521 | +4.3% | 0.00% | – |
Q3 2022 | $1,009,000 | -8.4% | 50,344 | +3.6% | 0.00% | – |
Q2 2022 | $1,101,000 | -13.7% | 48,599 | +0.7% | 0.00% | – |
Q1 2022 | $1,276,000 | -25.0% | 48,241 | -9.9% | 0.00% | – |
Q4 2021 | $1,702,000 | +69.5% | 53,549 | +17.4% | 0.00% | – |
Q3 2021 | $1,004,000 | -9.5% | 45,594 | -13.4% | 0.00% | – |
Q2 2021 | $1,110,000 | -6.6% | 52,675 | -7.4% | 0.00% | – |
Q1 2021 | $1,188,000 | -3.8% | 56,894 | -19.3% | 0.00% | – |
Q4 2020 | $1,235,000 | +30.1% | 70,472 | -10.9% | 0.00% | – |
Q3 2020 | $949,000 | -23.7% | 79,074 | +2.3% | 0.00% | – |
Q2 2020 | $1,244,000 | +788.6% | 77,306 | +570.4% | 0.00% | – |
Q1 2020 | $140,000 | -17.2% | 11,532 | -4.2% | 0.00% | – |
Q4 2019 | $169,000 | -3.4% | 12,034 | +22.7% | 0.00% | – |
Q3 2019 | $175,000 | – | 9,806 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,600,000 | $32,048,000 | 13.34% |
Lynx1 Capital Management LP | 613,071 | $12,280,000 | 11.08% |
Aquilo Capital Management, LLC | 1,507,109 | $30,187,000 | 10.88% |
COMMODORE CAPITAL LP | 2,615,762 | $52,394,000 | 8.42% |
MPM BioImpact LLC | 918,310 | $18,394,000 | 4.36% |
BVF INC/IL | 3,444,420 | $68,992,000 | 2.85% |
Boxer Capital, LLC | 1,900,000 | $38,057,000 | 2.14% |
Opaleye Management Inc. | 253,200 | $5,072,000 | 2.10% |
SILVERARC CAPITAL MANAGEMENT, LLC | 295,136 | $5,912,000 | 2.00% |
TCG Crossover Management, LLC | 300,000 | $6,009,000 | 1.80% |